Advanced glycation end products in myocardial reperfusion injury
- 183 Downloads
Advanced glycation end products (AGEs) are associated with cardiovascular diseases. Whether the AGE levels change during myocardial reperfusion injury is currently unknown. The aim of our study was to investigate the dynamics of AGEs in myocardial reperfusion injury and to discuss potential reasons for these changes. The dynamics of AGEs, pentosidine and neopterin in the plasma of patients with acute myocardial infarction (AMI) treated using thrombolysis (n = 40) were analyzed. In addition, AGEs were measured in patients with open heart surgery (n = 12) and rabbits with induced AMI (n = 9). In all three studies of myocardial reperfusion injury, a significant decrease of AGEs was observed (by 26 ± 19% in patients with AMI, by 23 ± 14% in patients with open heart surgery and by 39 ± 10% in rabbits with AMI within 1 day of reperfusion; p < 0.05 in all studies). In additional studies, an association between lower AGEs and an activated immune system (R 2 = 0.09; p < 0.01) and fasting (decrease by 38%; p < 0.01) was shown. AGEs decrease in reperfusion injury of the heart. Indices pointing towards the involvement of immune system activation and fasting are presented. Further studies focusing on the underlying mechanism and on the clinical value of the observed dynamics of AGEs are needed.
KeywordsCarbonyl stress Pentosidine Acute myocardial infarction Neopterin
The study was supported by research projects MSM 0021620807 and VMSP-II-0027-09.
- 9.van Heerebeek L, Hamdani N, Handoko ML, Falcao-Pires I, Musters RJ, Kupreishvili K, Ijsselmuiden AJJ, Schalkwijk CG, Bronzwaer JGF, Diamant M, Borbely A, Van der Velden J, Stienen GJM, Laarman GJ, Niessen HWM, Paulus WJ (2008) Diastolic stiffness of the failing diabetic heart—importance of fibrosis, advanced glycation end products, and myocyte resting tension. Circulation 117:43–51PubMedCrossRefGoogle Scholar
- 12.Dolhoferbliesener R, Lechner B, Deppisch R, Ritz E, Gerbitz KD (1995) Immunological determination of advanced glycosylation end-products in human blood and urine. Nephrol Dial Transplant 10:657–664Google Scholar
- 24.Steine K, Larsen JR, Stugaard M, Berg TJ, Brekke M, Dahl-Jorgensen K (2007) LV systolic impairment in patients with asymptomatic coronary heart disease and type I diabetes is related to coronary atherosclerosis, glycaemic control and advanced glycation endproducts. Eur J Heart Fail 9:1044–1050PubMedCrossRefGoogle Scholar
- 26.Koyama Y, Takeishi Y, Arimoto T, Niizeki T, Shishido T, Takahashi H, Nozaki N, Hirono O, Tsunoda Y, Nitobe J, Watanabe T, Kubota I (2007) High serum level of pentosidine, an advanced glycation end product (AGE), is a risk factor of patients with heart failure. J Card Fail 13:199–206PubMedCrossRefGoogle Scholar
- 27.Chrysohoou C, Pitsavos C, Aggelopoulos P, Skoumas J, Tsiamis E, Panagiotakos DB, Stefanadis C (2010) Serum glucose level at hospital admission correlates with left ventricular systolic dysfunction in nondiabetic, acute coronary patients: the Hellenic Heart Failure Study. Heart Vessels 25:209–216PubMedCrossRefGoogle Scholar
- 28.Heidland A, Sebekova K, Frangiosa A, De Santo LS, Cirillo M, Rossi F, Cotrufo M, Perna A, Klassen A, Schinzel R, De Santo NG (2004) Paradox of circulating advanced glycation end product concentrations in patients with congestive heart failure and after heart transplantation. Heart 90:1269–1274PubMedCrossRefGoogle Scholar
- 34.Zimmerman GA, Meistrell M, Bloom O, Cockroft KM, Bianchi M, Risucci D, Broome J, Farmer P, Cerami A, Vlassara H, Tracey KJ (1995) Neurotoxicity of advanced glycation endproducts during focal stroke and neuroprotective effects of aminoguanidine. Proc Natl Acad Sci USA 92:3744–3748PubMedCrossRefGoogle Scholar
- 36.Kilhovd BK, Juutilainen A, Lehto S, Ronnemaa T, Torjesen PA, Birkeland KI, Berg TJ, Hanssen KF, Laakso M (2005) High serum levels of advanced glycation end products predict increased coronary heart disease mortality in nondiabetic women but not in nondiabetic men—a population-based 18-year follow-up study. Arterioscler Thromb Vasc Biol 25:815–820PubMedCrossRefGoogle Scholar